<DOC>
	<DOCNO>NCT02107703</DOCNO>
	<brief_summary>The main purpose study compare progression-free survival woman hormone receptor positive ( HR+ ) , human epidermal growth factor receptor ( HER2 ) negative advanced breast cancer receive either abemaciclib+fulvestrant fulvestrant alone . Participants randomize abemaciclib placebo 2:1 ratio . The study last 9 month participant .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Combined With Fulvestrant Women With Hormone Receptor Positive HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Inclusion Criteria Have diagnosis HR+ , HER2 breast cancer Have locally advance disease amenable curative treatment surgery metastatic disease . In addition , participant must fulfill 1 follow criterion : relapse radiologic evidence progression receive neoadjuvant adjuvant endocrine therapy , subsequent endocrine therapy receive following progression relapse radiologic evidence progression within 1 year completion adjuvant endocrine therapy , subsequent endocrine therapy receive following progression relapse radiologic evidence progression 1 year completion adjuvant endocrine therapy subsequently relapse radiologic evidence progression receive treatment either antiestrogen aromatase inhibitor firstline endocrine therapy metastatic disease . Participants may receive 1 line endocrine therapy prior chemotherapy metastatic disease present de novo metastatic disease relapse radiologic evidence progression receive treatment either antiestrogen aromatase inhibitor first line endocrine therapy metastatic disease . Participants may receive 1 line endocrine therapy prior chemotherapy metastatic disease Have postmenopausal status due either surgical/natural menopause ovarian suppression ( initiate least 28 day prior Day 1 Cycle 1 ) gonadotropinreleasing hormone ( GnRH ) agonist goserelin Have negative serum pregnancy test baseline ( within 14 day prior randomization ) agree use medically approve precaution prevent pregnancy study 12 week follow last dose abemaciclib postmenopausal status due ovarian suppression GnRH agonist Have either measurable disease nonmeasurable bone disease Have performance status â‰¤1 ECOG scale Have discontinue previous therapy cancer ( include specifically , aromatase inhibitor , antiestrogens , chemotherapy , radiotherapy , immunotherapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( toxicity resolve either baseline least Grade 1 ) except residual alopecia peripheral neuropathy Exclusion Criteria Are currently receive investigational drug clinical trial participate type medical research judge scientifically medically compatible study Have visceral crisis , lymphangitic spread , leptomeningeal carcinomatosis visceral crisis mere presence visceral metastasis implies severe organ dysfunction assess symptom sign , laboratory study , rapid progression disease Have clinical evidence history central nervous system metastasis Have receive prior treatment chemotherapy ( except neoadjuvant/ adjuvant chemotherapy ) , fulvestrant , everolimus , CDK4/6 inhibitor Have receive treatment drug receive regulatory approval indication within 14 21 day prior randomization study drug nonmyelosuppressive myelosuppressive agent , respectively Have receive recent ( within 28 day prior randomization ) yellow fever vaccination Have major surgery within 14 day prior randomization study drug allow postoperative healing surgical wound site ( ) Have personal history within last 12 month follow condition : syncope cardiovascular etiology , ventricular tachycardia , ventricular fibrillation , sudden cardiac arrest Have inflammatory breast cancer history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy minimum 3 year Have receive autologous allogeneic stemcell transplant Have active bacterial fungal infection , detectable viral infection Have initiate bisphosphonates approve Receptor activator nuclear factor kappaB ( RANK ) ligand target agent &lt; 7 day prior randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MONARCH 2</keyword>
</DOC>